Ho Young Song

This inventor holds 27 USPTO granted patents and 39 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Antibody-Drug Conjugates. Top assignees: Legochem Biosciences, Inc., Electronics and Telecommunications Research Institute, Legochem Bioscience Ltd.. Active years: 1994-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ho Young Song. Retrieved from https://idiyas.com/inventor/ho-young-song-c8i963jr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 27 (Patent Applications = 39)

% Patents Active = 74.1

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 24)

Average Co-Inventor Count = 5.5

ph-index = 8

Forward Citations = 735(Granted Patents)

Location History:

Jinbuk-dong, Cheonju-si, Cheonrabuk-do, KR (1994)
Deajeon, KR (2023)
Daejeon, KR (2012 - 2024)

Company Filing History:

14 out of 25

Legochem Biosciences, Inc.

patents

7 out of 11,796

Electronics and Telecommunications Research Institute

patents

4 out of 4

Legochem Bioscience Ltd.

patents

4. 2 out of 264

The Green Cross Corporation

Ligachem Biosciences Inc.

9. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 1994-2025

Loading Chart...

Areas of Expertise:

Antibody-Drug Conjugates

Self-Immolative Groups

Pharmaceutical Compositions

Branched Linkers

Anti-CD19 Antibody

Anti-EGFR Antibody

Peptide Groups

Pyrrolobenzodiazepine Prodrug

Electric Power Control

QoS Communication

FXA Inhibitors

Endovascular Stents

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12398124 - Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same (2025-08-26),

2. 11975076 - Antibody-drug conjugates comprising branched linkers and methods related thereto (2024-05-07),

3. 11827703 - Compositions and methods related to anti-CD19 antibody drug conjugates (2023-11-28),

4. 11707533 - Antibody-drug conjugate comprising antibody against human ROR1 and use for the same (2023-07-25),

5. 11654197 - Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same (2023-05-23),

6. 11413353 - Conjugates comprising self-immolative groups and methods related thereto (2022-08-16),

7. 11173214 - Antibody-drug conjugates comprising branched linkers and methods related thereto (2021-11-16),

8. 11167040 - Conjugates comprising peptide groups and methods related thereto (2021-11-09),

9. 10980890 - Compounds comprising self-immolative group (2021-04-20),

10. 10484907 - Communication method and apparatus based on quality of service (QoS) in network slice-based mobile communication network (2019-11-19),

11. 10383949 - Compounds comprising self-immolative group (2019-08-20),

12. 10183997 - Compositions and methods related to anti-CD19 antibody drug conjugates (2019-01-22),

13. 10118965 - Compositions and methods related to anti-EGFR antibody drug conjugates (2018-11-06),

14. 9993568 - Compounds comprising self-immolative group (2018-06-12),

15. 9988372 - Crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition comprising same (2018-06-05),

Title: Innovative Contributions of Ho Young Song in Antibody-Drug Conjugates

Introduction

Ho Young Song, based in Daejeon, South Korea, is an accomplished inventor with a remarkable portfolio of 25 patents. His work primarily focuses on advancements in antibody-drug conjugates (ADCs), which are crucial in enhancing targeted drug delivery for cancer treatments.

Latest Patents

Ho Young Song's recent patents include innovative approaches to ADCs, including methods involving branched linkers. One of his significant inventions relates to ADCs in which multiple active agents are conjugated to an antibody via branched linkers. This invention allows for the coupling of two or more branched linkers to the antibody, enhancing therapeutic efficacy. Another noteworthy patent details compositions and methods related to anti-CD19 ADCs, featuring covalent linkers that connect active agents to anti-CD19 antibodies. This innovation has potential applications in various therapeutic, diagnostic, and prophylactic scenarios.

Career Highlights

Throughout his career, Ho Young Song has accumulated extensive experience in the biotechnology sector. He has worked at reputable organizations such as Legochem Biosciences, Inc. and the Electronics and Telecommunications Research Institute. His contributions have significantly impacted the development of targeted therapies.

Collaborations

In his journey as an inventor, Ho Young Song has collaborated with notable colleagues, including Yong Zu Kim and Jeiwook Chae. Their collective expertise and insights have likely fueled innovative advancements in their respective fields.

Conclusion

Ho Young Song's contributions to the field of antibody-drug conjugates underscore the importance of innovation in biomedical research. With his significant patent portfolio and collaborative spirit, he continues to forge paths toward effective therapies, reinforcing the impact of inventive minds in the healthcare industry.

Profile summary based on public USPTO records.